Antibody ID	ANTI0YJCXM
Antibody Name	Tratuzumab (P41C)
Synonyms	Tratuzumab (P41C)    Click to Show/Hide
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.016 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.018 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.026 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.028 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.538 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.594 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.728 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.17 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.39 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.43 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	27.52 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Ref 1	New shielded antibody